Literature DB >> 16368947

Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays.

Gabriella Sozzi1, Luca Roz, Davide Conte, Luigi Mariani, Francesca Andriani, Paolo Verderio, Ugo Pastorino.   

Abstract

Analysis of molecular markers in biological fluids has been proposed as a tool for early detection and monitoring of cancer. Circulating plasma DNA concentrations have been found to be higher in cancer patients than in cancer-free control subjects, but little is known about the effect of specimen storage on plasma DNA concentrations. Here we investigated the impact of long-term storage of both plasma samples and purified plasma DNA on the reproducibility of plasma DNA quantification as determined using real-time polymerase chain reaction analysis. The analysis was performed on samples from a subset of 34 lung cancer patients and 28 matched control subjects selected from 200 subjects in our previously published case-control study and from 117 cancer-free smokers enrolled in a lung cancer screening program. Two samples of plasma and isolated DNA were assessed for each patient, with a median of 41 months between the first and second assessments for participants in the case-control study and 9 months for participants in the screening study. DNA levels declined substantially between the two assessments at an average rate of approximately 30% per year. These data provide valuable information for the rational planning of retrospective studies of banked series of biological samples, particularly if collected over a long period of time, as can occur in large clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16368947     DOI: 10.1093/jnci/dji432

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  38 in total

1.  Ex vivo instability of glycated albumin: A role for autoxidative glycation.

Authors:  Joshua W Jeffs; Shadi Ferdosi; Hussein N Yassine; Chad R Borges
Journal:  Arch Biochem Biophys       Date:  2017-07-13       Impact factor: 4.013

2.  Plasma DNA restoration for PCR applications.

Authors:  Y R Arias; E F Carrillo; F A Aristizábal
Journal:  J Clin Pathol       Date:  2007-08       Impact factor: 3.411

Review 3.  Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.

Authors:  Paola Ulivi; Rosella Silvestrini
Journal:  Cell Oncol (Dordr)       Date:  2013-11-01       Impact factor: 6.730

4.  A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

Authors:  B T Li; A Drilon; M L Johnson; M Hsu; C S Sima; C McGinn; H Sugita; M G Kris; C G Azzoli
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

5.  Measurement of Differentially Methylated INS DNA Species in Human Serum Samples as a Biomarker of Islet β Cell Death.

Authors:  Sarah A Tersey; Jennifer B Nelson; Marisa M Fisher; Raghavendra G Mirmira
Journal:  J Vis Exp       Date:  2016-12-21       Impact factor: 1.355

6.  Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy.

Authors:  Apostolos Zaravinos; Spiros Tzoras; Stavros Apostolakis; Kyriakos Lazaridis; Demetrios A Spandidos
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

Review 7.  Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum.

Authors:  Mary Beth Terry; Jasmine A McDonald; Hui Chen Wu; Sybil Eng; Regina M Santella
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

8.  Circulating Tumor Nucleic Acids: Perspective in Breast Cancer.

Authors:  Ida Casciano; Angela Di Vinci; Barbara Banelli; Claudio Brigati; Alessandra Forlani; Giorgio Allemanni; Massimo Romani
Journal:  Breast Care (Basel)       Date:  2010-04-23       Impact factor: 2.860

9.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.

Authors:  Mattia Boeri; Carla Verri; Davide Conte; Luca Roz; Piergiorgio Modena; Federica Facchinetti; Elisa Calabrò; Carlo M Croce; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

10.  Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Authors:  R E Board; G Ellison; M C M Orr; K R Kemsley; G McWalter; L Y Blockley; S P Dearden; C Morris; M Ranson; M V Cantarini; C Dive; A Hughes
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.